About this Research Topic
Cancer immunotherapy has emerged as a powerful treatment option, leveraging the body’s immune system to fight malignancies. Despite remarkable successes, including prolonged survival and even complete remission in diverse cancers, challenges persist. Tumor cells often exploit mechanisms that help them evade immune detection, undermining the efficacy of current therapies. Innovative strategies such as immune checkpoint inhibitors and CAR T-cell therapies are revolutionizing treatment, yet resistance mechanisms and a variability in patient response highlight the need for advanced research in this domain.
This Research Topic aims to consolidate a diverse array of research findings and hypotheses that could enhance the effectiveness and applicability of cancer immunotherapy. By addressing the intrinsic mechanisms through which tumors evade immune destruction, this special issue seeks to foster the development of novel therapeutic strategies. Emphasizing clinical outcomes and the integration of treatments like CAR-NK cells, CAR-Macrophage therapy, and cancer vaccines, it intends to close the gap between experimental research and clinical application, advancing personalized medicine.
The primary focus of this research topic is to detail the interaction between cancer cells and the immune system within the confines of advanced therapeutic techniques. We welcome the submission of Original Research, Reviews, Mini-Review, Methods, Case reports, Clinical Trial Reports, and Perspective articles that cover, but are not limited to the following areas:
• The mechanisms of immune recognition and evasion by cancer cells
• The development of novel immunotherapeutic agents
• Clinical trial outcomes
• Biomarkers for predicting therapy response
• Strategies to overcome resistance to immunotherapy
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
This Research Topic aims to consolidate a diverse array of research findings and hypotheses that could enhance the effectiveness and applicability of cancer immunotherapy. By addressing the intrinsic mechanisms through which tumors evade immune destruction, this special issue seeks to foster the development of novel therapeutic strategies. Emphasizing clinical outcomes and the integration of treatments like CAR-NK cells, CAR-Macrophage therapy, and cancer vaccines, it intends to close the gap between experimental research and clinical application, advancing personalized medicine.
The primary focus of this research topic is to detail the interaction between cancer cells and the immune system within the confines of advanced therapeutic techniques. We welcome the submission of Original Research, Reviews, Mini-Review, Methods, Case reports, Clinical Trial Reports, and Perspective articles that cover, but are not limited to the following areas:
• The mechanisms of immune recognition and evasion by cancer cells
• The development of novel immunotherapeutic agents
• Clinical trial outcomes
• Biomarkers for predicting therapy response
• Strategies to overcome resistance to immunotherapy
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords: Cancer, Immune Plasticity, immune recognition, immune evasion, Immunotherapy, immunotherapeutic agents, Tumor Diseases
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
